Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Lundin Gold Declares Quarterly Dividends of US$1.15 per Share

View original at finance.yahoo.com
Lundin Gold Declares Quarterly Dividends of US$1.15 per Share Lundin Gold logo (CNW Group/Lundin Gold Inc.) VANCOUVER, BC, Feb. 19, 2026 /CNW/ - Lundin Gold Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company continues to demonstrate the quality of FDN and commitment to delivering meaningful returns to shareholders while advancing a growing pipeline of high value opportunities

    80% confidence
  • The quarterly dividend of US$1.15 per share reflects another period of strong performance and cash flow generation at Fruta del Norte and is based on returning 100% of normalized free cash flow, after payment of the fixed dividend, to shareholders

    80% confidence
  • Fruta del Norte is among the highest-grade operating gold mines in the world

    80% confidence
  • Lundin Gold's ability to consistently return capital to shareholders is driven by the exceptional margins and consistency of the Fruta del Norte asset

    80% confidence
  • The variable dividend will be equal to an amount per share based on at least 50% of the Company's normalized free cash flow during the preceding quarter, less the fixed dividend paid during such period

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Lundin Gold Declares Quarterly Dividends of US$1.15 per Share — Source | Via News | ViaNews Market